Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crop Life ScienceNSE:CLSL +5.08%55 Debt-to-EBITDA is 2.67 as of Mar. 2026, which is 17% above its 10-year median of 2.29. GuruFocus rates NSE:CLSL with a GF Score™ of 55/100 and a GF Value™ of ₹55.58 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 203 Agriculture companies, Crop Life Science ranks worse than 63.55% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Crop Life Science's Debt-to-EBITDA or its related term are showing as below:
NSE:CLSL'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.92 Med: 2.29 Max: 2.89
Current: 2.82
During the past 7 years, the highest Debt-to-EBITDA Ratio of Crop Life Science was 2.89. The lowest was 1.92. And the median was 2.29.
NSE:CLSL's Debt-to-EBITDA is ranked worse than 63.55% of 203
companies
in the Agriculture industry
Industry Median: 2.08
vs NSE:CLSL: 2.82
Crop Life Science (NSE:CLSL) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Crop Life Science Debt-to-EBITDA Related Terms
Crop Life Science Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Crop Life Science's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CLSL vs CTVA, CF, MOS: Debt-to-EBITDA Comparison
For the Agricultural Inputs subindustry, Crop Life Science's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crop Life Science Debt-to-EBITDA vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Crop Life Science's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Crop Life Science's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
Crop Life Science (NSE:CLSL) has a Debt-to-EBITDA of 2.67 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Crop Life Science. This is 17% above median its historical median of 2.29. Over the past decade, Crop Life Science's Debt-to-EBITDA has ranged from 1.92 to 2.89. According to the industry distribution chart, Crop Life Science ranks #129 out of 203 companies in the Agriculture industry, placing it in the top 63.5%.
Is Crop Life Science's Debt-to-EBITDA too high?
Crop Life Science's current Debt-to-EBITDA of 2.67 is 17% above median its 10-year median of 2.29. Over the past 10 years, this metric has ranged from a low of 1.92 to a high of 2.89. The Agriculture industry median Debt-to-EBITDA is 2.08. Crop Life Science's value of 2.67 is 28.4% above this industry median. Based on the distribution chart, Crop Life Science ranks #129 out of 203 companies in the Agriculture industry, which is below the industry midpoint. Overall, Crop Life Science has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Crop Life Science's Debt-to-EBITDA compare to CTVA and CF?
According to the Agriculture industry distribution chart, Crop Life Science ranks #129 out of 203 companies for Debt-to-EBITDA. This places Crop Life Science in the lower half of its industry. The industry median Debt-to-EBITDA is 2.08. Crop Life Science's value of 2.67 is 28.4% above this benchmark. Historically, Crop Life Science's own Debt-to-EBITDA has ranged from 1.92 to 2.89 over the past decade. While the company's 10-year median is 2.29 vs. the industry median of 2.08, Crop Life Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for an Agriculture company?
The median Debt-to-EBITDA among Agriculture companies is 2.08, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crop Life Science's current Debt-to-EBITDA of 2.67 is 28.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Crop Life Science. For the Agriculture industry, the median Debt-to-EBITDA is 2.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crop Life Science's current Debt-to-EBITDA is 2.67, which is 17% above median its own 10-year median of 2.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crop Life Science stock overvalued right now?
Based on GuruFocus' analysis, Crop Life Science (NSE:CLSL) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹55.58, compared to a current price of ₹64.10 — trading 15.3% above its estimated fair value. The current Debt-to-EBITDA is 2.67, which is 17% above median its 10-year median of 2.29 and 28.4% above the Agriculture industry median of 2.08. Crop Life Science's overall GF Score™ is 55/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Crop Life Science (NSE:CLSL), the current Debt-to-EBITDA is 2.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crop Life Science (NSE:CLSL) Overvalued in 2026?
Based on GuruFocus' analysis, Crop Life Science stock appears to be overvalued.
The current stock price of ₹64.10 is trading 15.3% above its estimated GF Value™ of ₹55.58.
GuruFocus considers Crop Life Science to be Modestly Overvalued.
Key valuation signals for NSE:CLSL:
Debt-to-EBITDA: 2.67 (17% above median its 10-year median of 2.29)
GF Value™: ₹55.58 vs. price of ₹64.10 (15.3% above fair value)
Industry Position: 28.4% above the Agriculture median (#129 of 203)
No single metric tells the full story. See the NSE:CLSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crop Life Science Ltd manufactures and distributes a broad range of crop protection chemicals, including pesticides, insecticides, fungicides, herbicides, micro fertilizers, bio-pesticides, bio-fertilizers, plant growth regulators, and soil plant health products. The company operates its manufacturing facility in Ankleshwar, Gujarat, leveraging technology to maintain quality standards. It serves agricultural markets within India and exports to countries including Indonesia, Bangladesh, Egypt, Myanmar, Vietnam, and Sudan. Segments include Agro chemicals and Agro trade. Revenue is generated through the sale of its agricultural chemicals and related products to farmers, distributors, and agri-businesses.
55GF Score
Get the complete analysis for NSE:CLSL
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CLSL has been successfully added to your 
